## Understanding PCOD Endocrinology ### The LH:FSH Ratio Myth **Key Point:** While an elevated LH:FSH ratio (>3:1 or even >2:1) is *common* in PCOD, it is **NOT a consistent or diagnostic finding** in all patients. The ratio varies widely and is neither sensitive nor specific for PCOD diagnosis. **High-Yield:** The Rotterdam criteria (2003) for PCOD diagnosis require **2 of 3** features: 1. Oligo/anovulation 2. Clinical or biochemical hyperandrogenism 3. Polycystic ovarian morphology on ultrasound Notably, an elevated LH:FSH ratio is **not part of the diagnostic criteria** because it is not uniformly present. ### Correct Features of PCOD | Feature | Prevalence/Truth | Evidence | |---------|------------------|----------| | Insulin resistance | 50–70% of PCOD patients | Well-established, independent of BMI | | Elevated LH:FSH ratio | Common but NOT universal | Found in ~60–70%, not diagnostic | | Hyperandrogenism | Present in ~70–80% | Clinical (hirsutism, acne) or biochemical (elevated testosterone) | | Impaired glucose tolerance | 30–40% of PCOD patients | Significantly elevated risk vs. general population | | Type 2 diabetes risk | 5–10-fold increased | Long-term metabolic consequence | **Clinical Pearl:** Many PCOD patients have a *normal* LH:FSH ratio but still meet diagnostic criteria through anovulation + hyperandrogenism + polycystic ovaries. The ratio should **not** be used as a standalone screening tool. **Warning:** Clinicians often over-rely on the LH:FSH ratio as a diagnostic marker. It is a supportive finding, not a requirement.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.